Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Tumors of the Lungs and Pleura
share announcement

Tumors of the Lungs and Pleura

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (15 February 2022) | Viewed by 4569

Special Issue Editor

Prof. Dr. Katalin Dobra

E-Mail Website
Guest Editor
Department of Laboratory Medicine Division of Pathology, Karolinska Institutet/Karolinska University Hospital, SE14186 Stockholm, Sweden
Interests: lung cancer; molecular profiling; precision medicine

Special Issue Information

Dear Colleagues,

Lung cancer is the third most common cancer and the most common cause of death from cancer worldwide. Early diagnosis is paramount for improved patient survival, as with advanced stages of the disease, the prognosis deteriorates dramatically.

Apart from tobacco smoking, inhaled carcinogen particles, asbestos and chronic inflammation also play role in the development of malignant tumors of the lungs and pleura.

Understanding of the multitude of molecular pathways involved in the initiation and progression of lung cancer, preventive measures, adequate smoke control policies, along with assessment of the risk to develop cancer, screening and managing early stage lung cancer, early cytological and histological diagnosis, molecular profiling and ex-vivo testing of tumor cells sensitivity/resistance profile may all pave the way for harmonized precision medicine approaches.

High quality manuscripts addressing all aspects of lung cancer and malignant mesothelioma are welcome to this Special Issue in a joint effort to better characterize and tailor the future treatment and management of lung cancer and malignant mesothelioma.

Prof. Dr. Katalin Dobra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • early diagnosis
  • screening
  • lung cancer
  • malignant mesothelioma
  • molecular profiling
  • precision medicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 3286 KiB  
Article
Novel Genetic Prognostic Signature for Lung Adenocarcinoma Identified by Differences in Gene Expression Profiles of Low- and High-Grade Histological Subtypes
by Chia-Ching Chang, Min-Shu Hsieh, Mong-Wei Lin, Yi-Hsuan Lee, Yi-Jing Hsiao, Kang-Yi Su, Te-Jen Su, Sung-Liang Yu and Jin-Shing Chen
Biomolecules 2022, 12(2), 160; https://doi.org/10.3390/biom12020160 - 19 Jan 2022
Cited by 4 | Viewed by 2146
Abstract
The 2021 WHO classification proposed a pattern-based grading system for early-stage invasive non-mucinous lung adenocarcinoma. Lung adenocarcinomas with high-grade patterns have poorer outcomes than those with lepidic-predominant patterns. This study aimed to establish genetic prognostic signatures by comparing differences in gene expression profiles [...] Read more.
The 2021 WHO classification proposed a pattern-based grading system for early-stage invasive non-mucinous lung adenocarcinoma. Lung adenocarcinomas with high-grade patterns have poorer outcomes than those with lepidic-predominant patterns. This study aimed to establish genetic prognostic signatures by comparing differences in gene expression profiles between low- and high-grade adenocarcinomas. Twenty-six (9 low- and 17 high-grade adenocarcinomas) patients with histologically “near-pure” patterns (predominant pattern comprising >70% of tumor areas) were selected retrospectively. Using RNA sequencing, gene expression profiles between the low- and high-grade groups were analyzed, and genes with significantly different expression levels between these two groups were selected for genetic prognostic signatures. In total, 196 significant candidate genes (164 upregulated and 32 upregulated in the high- and low-grade groups, respectively) were identified. After intersection with The Cancer Genome Atlas–Lung Adenocarcinoma prognostic genes, three genes, exonuclease 1 (EXO1), family with sequence similarity 83, member A (FAM83A), and disks large-associated protein 5 (DLGAP5), were identified as prognostic gene signatures. Two independent cohorts were used for validation, and the areas under the time-dependent receiver operating characteristic were 0.784 and 0.703 in the GSE31210 and GSE30219 cohorts, respectively. Our result showed the feasibility and accuracy of this novel three-gene prognostic signature for predicting the clinical outcomes of lung adenocarcinoma. Full article
(This article belongs to the Special Issue Tumors of the Lungs and Pleura)
►▼ Show Figures

Figure 1

13 pages, 742 KiB  
Article
Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics
by Kajsa Ericson Lindquist, Inga Gudinaviciene, Nektaria Mylona, Rodrigo Urdar, Maria Lianou, Eva Darai-Ramqvist, Felix Haglund, Mátyás Béndek, Erika Bardoczi, Katalin Dobra and Hans Brunnström
Biomolecules 2021, 11(11), 1721; https://doi.org/10.3390/biom11111721 - 18 Nov 2021
Cited by 2 | Viewed by 1810
Abstract
Objectives: Accurate and reliable diagnostics are crucial as histopathological type influences selection of treatment in lung cancer. The aim of this study was to evaluate real-world accuracy and use of immunohistochemical (IHC) staining in lung cancer diagnostics. Materials and Methods: The diagnosis and [...] Read more.
Objectives: Accurate and reliable diagnostics are crucial as histopathological type influences selection of treatment in lung cancer. The aim of this study was to evaluate real-world accuracy and use of immunohistochemical (IHC) staining in lung cancer diagnostics. Materials and Methods: The diagnosis and used IHC stains for small specimens with lung cancer on follow-up resection were retrospectively investigated for a 15-month period at two major sites in Sweden. Additionally, 10 pathologists individually suggested diagnostic IHC staining for 15 scanned bronchial and lung biopsies and cytological specimens. Results: In 16 (4.7%) of 338 lung cancer cases, a discordant diagnosis of potential clinical relevance was seen between a small specimen and the follow-up resection. In half of the cases, there was a different small specimen from the same investigational work-up with a concordant diagnosis. Diagnostic inaccuracy was often related to a squamous marker not included in the IHC panel (also seen for the scanned cases), the case being a neuroendocrine tumor, thyroid transcription factor-1 (TTF-1) expression in squamous cell carcinomas (with clone SPT24), or poor differentiation. IHC was used in about 95% of cases, with a higher number of stains in biopsies and in squamous cell carcinomas and especially neuroendocrine tumors. Pre-surgical transthoracic samples were more often diagnostic than bronchoscopic ones (72–85% vs. 9–53% for prevalent types). Conclusions: Although a high overall diagnostic accuracy of small specimens was seen, small changes in routine practice (such as consequent inclusion of p40 and TTF-1 clone 8G7G3/1 in the IHC panel for non-small cell cancer with unclear morphology) may lead to improvement, while reducing the number of IHC stains would be preferable from a time and cost perspective. Full article
(This article belongs to the Special Issue Tumors of the Lungs and Pleura)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop